Elucidation of human amphotericin B pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling

Pharmaceutical Research

Volumn 15, Issue 10, 1998, Pages 1630-1636

  Robbie, Gabriel ^a   Chiou, Win L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Amphotericin B; Disposition function differences; Gender differences; Human; Interspecies scaling; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B;

ANIMAL EXPERIMENT; ARTICLE; CARDIOTOXICITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BLOOD PROTEINS; DOGS; FEMALE; HUMANS; MALE; MICE; PROTEIN BINDING; RABBITS; RATS; SPECIES SPECIFICITY;

EID: 0031719267     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011923704731     Document Type: Article

References (32)

1. M. P. Nagata, C. A. Gentry, and E. M. Hampton. Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? Annals Pharmacother. 30:811-818 (1996).
2. G. G. Chabot, R. Pazdur, F. A. Valeriote, and L. H. Baker. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J. Pharm. Sci. 78:307-310 (1989).
3. J. R. Starke, E. O. Mason, Jr., W. G. Kramer and S. L. Kaplan. Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 155:766-774 (1987).
4. G. Koren, A. Lau, J. Klein, C. Golas, M. Bologa-Campeanu, S. Soldin. S. M. MacLeod, and C. Prober. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J. Pediatr. 113:559-563 (1988).
5. A. J. Atkinson, Jr., and J. E. Bennett. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:271-276 (1978).
6. H. H. Chow, Y. Wu, and M. Mayersohn. Pharmacokinetics of amphotericin B in rats as a function of dose following constantrate intravenous infusion. Biopharm. Drug Disposit. 16:461-473 (1995).
7. L. H. Wang, R. M. Fielding, P. C. Smith, and L. S. S. Guo. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil®) and Fungizone® after repeated dosing in rats. Pharm. Res. 12:275-283 (1995).
8. H. H. Chow, Y. Cai, and M. Mayersohn. Disposition kinetics of amphotericin B in rats: the influence of dose. Drug Metab. Dispos. 20:432-435 (1992).
9. R. M. Fielding, P. C. Smith, L. H. Wang, J. Porter, and L. S. S. Guo. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208-1213 (1991).
10. K. Wasan, K. Vadiei, G. Lopez-Berestein, and D. R. Luke. Pharmacokinetics, tissue distribution and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 161:562-566 (1990).
11. K. Vadiei, G. Lopez-Berestein, and D. R. Luke. Disposition and toxicity of amphotericin B in the hyperlipedimic zucker rat model. Int. J. Obesity 14:465-472 (1990).
12. H. Kim, D. Loebenberg, A. Marco, S. Symchowicz, and C. Lin. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs and cynomolgus monkeys. Antimicrob. Agents Chemother. 26:446-449 (1984).
13. J. A. Gondal, R. P. Swartz, and A. Rahman. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544-1548 (1989).
14. J. W. Lee, M. A. Amantea, P. A. Francis, E. E. Navarro, J. Bacher, P. A. Pizzo, and T. J. Walsh. Pharmacokinetics and safety of a unilammelar liposomal formulation of amphotericin B (ambisome) in rabbits. Antimicrob. Agents Chemother. 38:713-718 (1994).
15. L. C. Edmonds, L. Davidson, and J. S. Bertino. Effect of variation in infusion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate. J. Antimicrob. Chemother. 28:919-924 (1991).
16. P. C. Craven, T. M. Ludden, D. J. Drutz, W. Rogers, K. A. Haegele, and H. B. Skrdlant. Excretion pathways of amphotericin B. J. Infect. Dis. 140:329-341 (1979).
17. F. A. Jagdis, P. D. Hoeprich, R. M. Lawrence, and C. P. Schaffner. Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate. Macaca mulatta. Antimicrob. Agents Chemother. 12:582-590 (1977).
18. A. Hutchaleelaha, H. H. Chow, and M. Mayersohn. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J. Pharm. Pharmacol. 49:178-183 (1997).
19. E. R. Block, J. E. Bennett, L. G. Livoti, W. J. Klein, R. R. MacGregor, and L. Henderson. Fluocytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Ann. Intern. Med. 80:613-617 (1974).
20. W. L. Chiou, G. Robbie, S. M. Chung, T. C. Wu, and C. Ma. Relationship of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharm. Res. (in press).
21. C. L. Golas, C. G. Prober, S. M. MacLeod, and S. J. Soldin. Measurement of amphotericin B in serum or plasma by high-performance liquid chromatography. J. Chromatogr. 278:387-395, (1983).
22. W. L. Chiou. Critical evaluation of the potential error in pharmacokinetic studies of using linear trapezoidal rule method for calculation of the area under the plasma level-time curve. J. Pharmacokin. Biopharm. 6:539-546 (1978).
23. W. L. Chiou, Compartment- and model-independent linear plateau principle of drugs during a constant-rate absorption or intravenous infusion. J. Pharmacokinet. Biopharm. 8:311-318 (1980).
24. W. L. Chiou. New calculation method of mean total body clearance of drugs and its application to dosage regimens. J. Pharm. Sci. 69:90-91 (1980).
25. W. L. Chiou. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. J. Pharm. Sci. 68:1067-1069 (1979).
26. H. Boxenbaum. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokin. Biopharm. 10:201-227 (1982).
27. M. A. Gales and B. J. Gales. Rapid infusion of amphotericin B in dextrose. Annals Pharmacother. 29:523-529 (1995).
28. D. D. Bindschadler and J. E. Bennett. A Pharmacologie guide to the clinical use of amphotericin B. J. Infect. Dis. 120:427-436 (1969).
29. D. J. Morgan, M. S. Ching, K. Raymond, R. W. Bury, L. Mashford, B. Kong, J. Sabto, W. Gurr, and A. A. Somogyi Elimination of amphotericin B in impaired renal function. Clin. Pharmacol. Ther. 34:248-253 (1983).
30. J. M. Benson and M. C. Nahata. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33:1989-1993 (1989).
31. M. Bouley, M. Todd, P. Chavanet, and O. Petitjean. The penetration of amphotericin B from an intralipid formulation into fibrin loci in a rabbit model of candidiasis. Biopharm. Drug Disposit. 15:485-492 (1994).
32. R. M. Fielding, A. W. Singer, L. H. Wang, S. Babbar, and L. S. S. Guo. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36:299-307 (1992).